0.828
0.06 (7.39%)
| Penutupan Terdahulu | 0.771 |
| Buka | 0.752 |
| Jumlah Dagangan | 3,199,903 |
| Purata Dagangan (3B) | 10,943,535 |
| Modal Pasaran | 81,113,328 |
| Harga / Jualan (P/S) | 347.79 |
| Harga / Buku (P/B) | 0.910 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Nov 2025 |
| EPS Cair (TTM) | -0.800 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 17.35% |
| Nisbah Semasa (MRQ) | 7.80 |
| Aliran Tunai Operasi (OCF TTM) | -62.16 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -37.33 M |
| Pulangan Atas Aset (ROA TTM) | -39.82% |
| Pulangan Atas Ekuiti (ROE TTM) | -79.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | aTyr Pharma, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.0 |
| Purata | -0.50 |
|
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 2.23% |
| % Dimiliki oleh Institusi | 69.63% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Tikvah Management Llc | 30 Sep 2025 | 460,833 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1.00 (RBC Capital, 20.80%) | Pegang |
| 1.00 (Wells Fargo, 20.80%) | Pegang | |
| Median | 1.00 (20.80%) | |
| Purata | 1.00 (20.80%) | |
| Jumlah | 2 Pegang | |
| Harga Purata @ Panggilan | 0.949 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 07 Nov 2025 | 1.00 (20.80%) | Pegang | 0.817 |
| 16 Sep 2025 | 1.50 (81.20%) | Pegang | 1.08 | |
| Wells Fargo | 16 Sep 2025 | 1.00 (20.80%) | Pegang | 1.08 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |